JP2016532657A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016532657A5 JP2016532657A5 JP2016521344A JP2016521344A JP2016532657A5 JP 2016532657 A5 JP2016532657 A5 JP 2016532657A5 JP 2016521344 A JP2016521344 A JP 2016521344A JP 2016521344 A JP2016521344 A JP 2016521344A JP 2016532657 A5 JP2016532657 A5 JP 2016532657A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- oral dosage
- cancer
- disease
- lactose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000006186 oral dosage form Substances 0.000 claims 52
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 21
- 206010028980 Neoplasm Diseases 0.000 claims 20
- 201000011510 cancer Diseases 0.000 claims 18
- 239000000203 mixture Substances 0.000 claims 14
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 12
- 229920002472 Starch Polymers 0.000 claims 12
- 229960001375 lactose Drugs 0.000 claims 12
- 239000008101 lactose Substances 0.000 claims 12
- 239000000314 lubricant Substances 0.000 claims 12
- 239000008107 starch Substances 0.000 claims 12
- 235000019698 starch Nutrition 0.000 claims 12
- 201000010099 disease Diseases 0.000 claims 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims 11
- 229940126062 Compound A Drugs 0.000 claims 10
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 10
- 229920000881 Modified starch Polymers 0.000 claims 9
- 235000021355 Stearic acid Nutrition 0.000 claims 9
- 229960004977 anhydrous lactose Drugs 0.000 claims 9
- 208000035475 disorder Diseases 0.000 claims 9
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 9
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 9
- 239000008117 stearic acid Substances 0.000 claims 9
- 206010060862 Prostate cancer Diseases 0.000 claims 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 5
- 239000002775 capsule Substances 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 239000002552 dosage form Substances 0.000 claims 5
- 229940002612 prodrug Drugs 0.000 claims 5
- 239000000651 prodrug Substances 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- 208000011580 syndromic disease Diseases 0.000 claims 5
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 4
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 238000005303 weighing Methods 0.000 claims 4
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 3
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 3
- 206010034277 Pemphigoid Diseases 0.000 claims 3
- 206010039491 Sarcoma Diseases 0.000 claims 3
- 206010047115 Vasculitis Diseases 0.000 claims 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 3
- 206010025135 lupus erythematosus Diseases 0.000 claims 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 208000007465 Giant cell arteritis Diseases 0.000 claims 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000003423 Mucocele Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010065159 Polychondritis Diseases 0.000 claims 2
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 2
- 239000003098 androgen Substances 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 206010043207 temporal arteritis Diseases 0.000 claims 2
- XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 208000008190 Agammaglobulinemia Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 206010001935 American trypanosomiasis Diseases 0.000 claims 1
- 206010073128 Anaplastic oligodendroglioma Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 206010006143 Brain stem glioma Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000024699 Chagas disease Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 208000011038 Cold agglutinin disease Diseases 0.000 claims 1
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 claims 1
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 claims 1
- 206010011686 Cutaneous vasculitis Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 201000001342 Fallopian tube cancer Diseases 0.000 claims 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010016935 Follicular thyroid cancer Diseases 0.000 claims 1
- 208000001034 Frostbite Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 1
- 206010021263 IgA nephropathy Diseases 0.000 claims 1
- 208000027601 Inner ear disease Diseases 0.000 claims 1
- 208000000209 Isaacs syndrome Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000017119 Labyrinth disease Diseases 0.000 claims 1
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 claims 1
- 208000018142 Leiomyosarcoma Diseases 0.000 claims 1
- 208000000185 Localized scleroderma Diseases 0.000 claims 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 claims 1
- 206010064281 Malignant atrophic papulosis Diseases 0.000 claims 1
- 208000009018 Medullary thyroid cancer Diseases 0.000 claims 1
- 208000027530 Meniere disease Diseases 0.000 claims 1
- 206010059282 Metastases to central nervous system Diseases 0.000 claims 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 201000009623 Myopathy Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims 1
- 206010072359 Neuromyotonia Diseases 0.000 claims 1
- 201000010133 Oligodendroglioma Diseases 0.000 claims 1
- 208000025174 PANDAS Diseases 0.000 claims 1
- 208000021155 Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 240000000220 Panda oleosa Species 0.000 claims 1
- 235000016496 Panda oleosa Nutrition 0.000 claims 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims 1
- 201000011152 Pemphigus Diseases 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 208000003782 Raynaud disease Diseases 0.000 claims 1
- 206010038019 Rectal adenocarcinoma Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000004346 Smoldering Multiple Myeloma Diseases 0.000 claims 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 1
- 208000001106 Takayasu Arteritis Diseases 0.000 claims 1
- 241000223109 Trypanosoma cruzi Species 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 206010002224 anaplastic astrocytoma Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000005000 autoimmune gastritis Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 239000000090 biomarker Substances 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 208000000594 bullous pemphigoid Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 201000003278 cryoglobulinemia Diseases 0.000 claims 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 230000002518 glial effect Effects 0.000 claims 1
- 208000024963 hair loss Diseases 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 208000029824 high grade glioma Diseases 0.000 claims 1
- 208000018821 hormone-resistant prostate carcinoma Diseases 0.000 claims 1
- 208000015266 indolent plasma cell myeloma Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000010260 leiomyoma Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000011486 lichen planus Diseases 0.000 claims 1
- 201000000564 macroglobulinemia Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 201000011614 malignant glioma Diseases 0.000 claims 1
- 208000006178 malignant mesothelioma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 206010027191 meningioma Diseases 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 201000005962 mycosis fungoides Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims 1
- 201000011519 neuroendocrine tumor Diseases 0.000 claims 1
- 230000000683 nonmetastatic effect Effects 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000005163 papillary serous adenocarcinoma Diseases 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 201000002628 peritoneum cancer Diseases 0.000 claims 1
- 210000004786 perivascular cell Anatomy 0.000 claims 1
- 201000006292 polyarteritis nodosa Diseases 0.000 claims 1
- 238000010837 poor prognosis Methods 0.000 claims 1
- 208000012934 primary antiphospholipid syndrome Diseases 0.000 claims 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 201000001281 rectum adenocarcinoma Diseases 0.000 claims 1
- 208000009169 relapsing polychondritis Diseases 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 208000012048 secondary antiphospholipid syndrome Diseases 0.000 claims 1
- 201000009295 smoldering myeloma Diseases 0.000 claims 1
- 208000010721 smoldering plasma cell myeloma Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 claims 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361888419P | 2013-10-08 | 2013-10-08 | |
| US61/888,419 | 2013-10-08 | ||
| PCT/US2014/059424 WO2015054199A1 (en) | 2013-10-08 | 2014-10-07 | Formulations of (s)-3-(4-((4-(morpholinomethyl)benzyloxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016532657A JP2016532657A (ja) | 2016-10-20 |
| JP2016532657A5 true JP2016532657A5 (enExample) | 2017-11-16 |
| JP6562907B2 JP6562907B2 (ja) | 2019-08-21 |
Family
ID=51743584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016521344A Active JP6562907B2 (ja) | 2013-10-08 | 2014-10-07 | （ｓ）−３−（４−（（４−（モルホリノメチル）ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオンの製剤 |
Country Status (35)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2536706T3 (pl) | 2010-02-11 | 2017-10-31 | Celgene Corp | Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania |
| PT2882441T (pt) | 2012-08-09 | 2020-06-29 | Celgene Corp | Tratamento de doenças associadas à imunidade e inflamatórias |
| US20150038511A1 (en) | 2012-08-09 | 2015-02-05 | Celgene Corporation | Treatment of immune-related and inflammatory diseases |
| US9695145B2 (en) | 2013-01-22 | 2017-07-04 | Celgene Corporation | Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof |
| ES2969532T3 (es) * | 2014-05-19 | 2024-05-21 | Celgene Corp | 3-(4-((4-(Morfolinometil-bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona para el tratamiento de lupus eritematoso sistémico |
| ITUB20160650A1 (it) * | 2016-02-11 | 2017-08-11 | Dipharma S A | Formulazioni farmaceutiche solide stabili contenenti 2-(2-nitro-4-trifluorometilbenzoil)-1,3-cicloesandione |
| US11529339B2 (en) * | 2018-10-01 | 2022-12-20 | Celgene Corporation | Combination therapy for the treatment of cancer |
| WO2020097403A1 (en) | 2018-11-08 | 2020-05-14 | Juno Therapeutics, Inc. | Methods and combinations for treatment and t cell modulation |
| CA3126067A1 (en) * | 2019-01-09 | 2020-07-16 | Celgene Corporation | Pharmaceutical compositions comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same |
| US20220401483A1 (en) | 2019-11-07 | 2022-12-22 | Juno Therapeutics, Inc. | Combination of a t cell therapy and (s)-3-[4-(4-morpholin-4-ylmethyl-benzyloxy)-l-oxo-l,3-dihydro-isoindol-2-yl]-piperidine-2,6-dione |
| CN115315260A (zh) * | 2019-12-02 | 2022-11-08 | 新基公司 | 治疗癌症的疗法 |
| BR112022026090A2 (pt) * | 2020-06-25 | 2023-01-17 | Celgene Corp | Métodos para tratar câncer com terapias de combinação |
| KR20230041707A (ko) * | 2020-07-17 | 2023-03-24 | 제론 코포레이션 | 피하 텔로머라제 억제제 조성물 및 이의 사용 방법 |
| WO2024064646A1 (en) | 2022-09-20 | 2024-03-28 | Celgene Corporation | Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same |
| WO2025076472A1 (en) | 2023-10-06 | 2025-04-10 | Juno Therapeutics, Inc. | Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995003009A1 (en) | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
| WO1995003807A1 (en) | 1993-07-27 | 1995-02-09 | The University Of Sydney | Treatment of age-related macular degeneration |
| IT1274549B (it) | 1995-05-23 | 1997-07-17 | Indena Spa | Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno |
| US5800819A (en) | 1996-01-25 | 1998-09-01 | National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology | Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease |
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| US6015803A (en) | 1998-05-04 | 2000-01-18 | Wirostko; Emil | Antibiotic treatment of age-related macular degeneration |
| US6225348B1 (en) | 1998-08-20 | 2001-05-01 | Alfred W. Paulsen | Method of treating macular degeneration with a prostaglandin derivative |
| US6001368A (en) | 1998-09-03 | 1999-12-14 | Protein Technologies International, Inc. | Method for inhibiting or reducing the risk of macular degeneration |
| AU2002343220A1 (en) | 2001-11-09 | 2003-05-19 | Matsushita Electric Industrial Co., Ltd. | Moving picture coding method and apparatus |
| US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
| US20050203142A1 (en) | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
| US20040091455A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
| US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| US20050100529A1 (en) | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
| US20050143344A1 (en) | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
| NZ550026A (en) | 2004-03-22 | 2009-10-30 | Celgene Corp | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders |
| AU2005237490A1 (en) | 2004-04-23 | 2005-11-10 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension |
| KR20070086000A (ko) | 2004-11-12 | 2007-08-27 | 셀진 코포레이션 | 기생충성 질병의 치료 및 관리를 위한 면역조절성 화합물을사용하는 방법 및 조성물 |
| MX2007006063A (es) | 2004-11-23 | 2007-07-11 | Celgene Corp | Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de lesion al sistema nervioso central. |
| RS52704B (sr) | 2005-06-30 | 2013-08-30 | Celgene Corporation | Postupci za dobijanje 4-amino-2-(2,6-dioksopiperidin-3-il) izoindolin-1,3-dionskih jedinjenja |
| BRPI0614995A2 (pt) | 2005-08-31 | 2010-01-12 | Celgene Corp | composto ou um sal, solvato ou estereoisemero farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de uma quantidade terapêutica ou profilaticamente eficaz de um composto ou um sal, solvato ou estereoisemero farmaceuticamente aceitável do mesmo, e, forma de dosagem unitária única |
| JP5523831B2 (ja) | 2006-08-30 | 2014-06-18 | セルジーン コーポレイション | ５−置換イソインドリン化合物 |
| US8877780B2 (en) | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
| RU2009114159A (ru) | 2006-09-15 | 2010-10-20 | Селджин Корпорейшн (Us) | N-метиламинометилизоидольные соединения, композиции, включающие их, и способы их применения |
| LT2420498T (lt) | 2006-09-26 | 2017-10-25 | Celgene Corporation | 5-pakeistieji chinazolinono dariniai, kaip priešvėžiniai agentai |
| KR101791757B1 (ko) | 2007-03-20 | 2017-10-30 | 셀진 코포레이션 | 4'-ｏ-치환된 아이소인돌린 유도체 및 이를 포함하는 조성물 및 이의 사용 방법 |
| EP3199149A1 (en) | 2009-05-19 | 2017-08-02 | Celgene Corporation | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
| PL2536706T3 (pl) * | 2010-02-11 | 2017-10-31 | Celgene Corp | Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania |
-
2014
- 2014-07-10 UA UAA201605023A patent/UA117141C2/uk unknown
- 2014-10-07 AR ARP140103744A patent/AR100663A1/es unknown
- 2014-10-07 LT LTEP14786429.2T patent/LT3054927T/lt unknown
- 2014-10-07 PE PE2016000431A patent/PE20160550A1/es unknown
- 2014-10-07 TR TR2019/05874T patent/TR201905874T4/tr unknown
- 2014-10-07 HU HUE14786429 patent/HUE044186T2/hu unknown
- 2014-10-07 CN CN201480055238.2A patent/CN105899196B/zh active Active
- 2014-10-07 EA EA201690741A patent/EA032421B1/ru not_active IP Right Cessation
- 2014-10-07 PT PT14786429T patent/PT3054927T/pt unknown
- 2014-10-07 TW TW103134936A patent/TW201605493A/zh unknown
- 2014-10-07 NZ NZ716856A patent/NZ716856A/en unknown
- 2014-10-07 RS RS20190490A patent/RS58688B1/sr unknown
- 2014-10-07 BR BR112016007729-6A patent/BR112016007729B1/pt active IP Right Grant
- 2014-10-07 AU AU2014332171A patent/AU2014332171C1/en active Active
- 2014-10-07 SI SI201431178T patent/SI3054927T1/sl unknown
- 2014-10-07 MX MX2016004342A patent/MX2016004342A/es unknown
- 2014-10-07 CA CA2921436A patent/CA2921436C/en active Active
- 2014-10-07 DK DK14786429.2T patent/DK3054927T3/da active
- 2014-10-07 SG SG11201600996UA patent/SG11201600996UA/en unknown
- 2014-10-07 PL PL14786429T patent/PL3054927T3/pl unknown
- 2014-10-07 ES ES14786429T patent/ES2723891T3/es active Active
- 2014-10-07 JP JP2016521344A patent/JP6562907B2/ja active Active
- 2014-10-07 KR KR1020167009333A patent/KR102272274B1/ko active Active
- 2014-10-07 WO PCT/US2014/059424 patent/WO2015054199A1/en not_active Ceased
- 2014-10-07 HR HRP20190733TT patent/HRP20190733T1/hr unknown
- 2014-10-07 SM SM20190231T patent/SMT201900231T1/it unknown
- 2014-10-07 EP EP14786429.2A patent/EP3054927B1/en active Active
- 2014-10-07 US US14/508,719 patent/US10080801B2/en not_active Ceased
-
2016
- 2016-02-12 PH PH12016500301A patent/PH12016500301A1/en unknown
- 2016-03-08 IL IL244494A patent/IL244494B/en active IP Right Grant
- 2016-03-15 CR CR20160131A patent/CR20160131A/es unknown
- 2016-04-03 SA SA516370860A patent/SA516370860B1/ar unknown
- 2016-04-06 NI NI201600048A patent/NI201600048A/es unknown
- 2016-04-08 CL CL2016000816A patent/CL2016000816A1/es unknown
-
2019
- 2019-05-03 CY CY20191100467T patent/CY1121689T1/el unknown
-
2020
- 2020-09-23 US US17/030,272 patent/USRE49647E1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016532657A5 (enExample) | ||
| HRP20190733T1 (hr) | Formulacije (s)-3-(4-((4-(morfolinometil)benziloksi)-1-oksoizoindolin-2-il)piperidin-2,6-diona | |
| JP2016505019A5 (enExample) | ||
| JP2017526662A5 (enExample) | ||
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| JP2013507415A5 (enExample) | ||
| JP2016508505A5 (enExample) | ||
| CN107548391A (zh) | 嘧啶或吡啶类化合物、其制备方法和医药用途 | |
| CY1119356T1 (el) | Πυριδινυλ και συντηγμενα παραγωγα πυριδινυλ τριαζολονης | |
| MX2021001583A (es) | Formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi ] fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboración y métodos de uso. | |
| AR102003A1 (es) | Compuestos de aminopiridiloxipirazol | |
| MX2016014574A (es) | El uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de mama triple-negativo. | |
| JP2017517506A5 (enExample) | ||
| AR077292A1 (es) | Derivados de piperazin - quinolin sulfonamidas y composiciones farmaceuticas | |
| JP2015508103A5 (enExample) | ||
| JP2016040288A5 (enExample) | ||
| MY189345A (en) | Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient | |
| JP2016525097A5 (enExample) | ||
| JP2015502926A5 (enExample) | ||
| JP2016509051A5 (enExample) | ||
| JP2014521609A5 (enExample) | ||
| RU2016135192A (ru) | Дейтерированные соединения хиназолинона и содержащие их фармацевтические композиции | |
| JP2012504631A5 (enExample) | ||
| RU2011153613A (ru) | Аминопиразол триазолотиадиазольные ингибиторы протеинкиназы с-мет | |
| JP2014005265A5 (enExample) |